Prostate cancer Prostate cancer
Conditions
Interventions
Pilot clinical trial of targeted therapy for localized prostate cancer
Sponsors
Ukimura Osamu
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: [1] Localization of cancer lesions was confirmed (limited to one side or confined to the front side in MRI imaging technology of prostate cancer and 3-dimensional real-time ultrasonic guided needle biopsy technology) In the histological diagnosis of cancer, it is "case of cancer lesion to be clinically treated" [2] Cases with distant distance (> 5 mm) from cancer and neighboring organs (especially urethral sphincter related to urinary prohibition and neurovascular bundle including erectile nerve) [3] A case with PS (ECOG) 0-1 [4] Age: 50-85 [5] A case who have written informed consent before enrollment in the study
Exclusion criteria
Exclusion criteria: 1) Patients with distant metastasis detected by CT and bone scintigraphy 2) Patients with tumors in contact with the rectal wall (to avoid rectal thermal damage during microwave coagulation) 3) Patients with pacemakers (to avoid the risk of microwave interference) 4) Patients who cannot undergo transrectal ultrasound because the rectum is closed 5) Patients with coagulation abnormalities (prothrombin time <50% or platelet count <60,000 / mm3) or taking anti-thrombotic drugs and related drugs cannot be withdrawn Patient 6) Patients with contraindications for MRI pretreatment, MRI, and contrast MRI 7) In the past, pharmacotherapy for prostate cancer (in the case of drugs with hormonal effects, judge at the end of the hormonal effect) and radiation therapy Patient who performed 8) Patients who have been treated with anti-androgenic hormone for benign prostatic hyperplasia in the past 9) Patients with active double cancer 10) Patients whose main organ functions are not maintained (Severe ECG abnormalities, severe arrhythmias, angina pectoris, heart failure, myocardial infarction) 11) Patients with uncontrollable infections (including hepatitis and active tuberculosis) 12) Patients with severe mental illness 13) Other patients who are judged to be ineligible by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life cancer control (effects on cancer control by MRI image) | — |
Contacts
Public ContactOsamu Ukimura
University Hospital, Kyoto Prefectural University of Medicine
Outcome results
None listed